Test more accurately identifies four mutations for which FDA-approved drugs exist and offers faster turn-around time between initial testing and commencement of therapy A multi-center study led by researchers at The University of Texas MD Anderson Cancer Center revealed that a liquid biopsy test called Guardant360®, is comparable to standard tissue biopsies in detection of advanced non-small cell lung cancer (NSCLC), has a faster turn-around time, and has the potential to more specifically pinpoint biomarkers crucial for molecular therapy. […]